基质金属蛋白酶-7作为特发性肺纤维化血液生物标志物的系统评价与个体参与者数据荟萃分析
该研究通过系统评价和个体参与者数据荟萃分析,评估基线及3个月变化基质金属蛋白酶-7(MMP-7)对未治疗特发性肺纤维化(IPF)患者的预后价值。纳入9项研究共1664例参与者,结果显示基线MMP-7水平与死亡风险增加(aHR 1.23,95%CI 1.03-1.48)和疾病进展(aOR 1.27,95%CI 1.11-1.46)独立相关,而3个月变化与结局无关。
要点
- 基线MMP-7水平升高与未治疗IPF患者死亡风险增加独立相关。
- 基线MMP-7水平升高与12个月内疾病进展风险增加独立相关。
- 短期(3个月)MMP-7变化未显示与疾病进展相关。
核心结论
- 基线MMP-7水平较高与未治疗IPF患者不良结局风险增加独立相关。
- 短期MMP-7变化未反映疾病进展。
研究设计与样本
- 系统评价与个体参与者数据荟萃分析,检索电子数据库至2020年11月12日。
- 纳入前瞻性研究,报告未治疗IPF患者结局,按至少一种预设生物标志物分层,测量基线或3个月变化。
- 共识别12项研究,其中9项提供个体参与者数据,共1664例参与者。
主要发现
- 基线MMP-7水平与死亡风险增加相关(校正风险比1.23,95%CI 1.03-1.48;I2=64.3%)。
- 基线MMP-7水平与疾病进展相关(校正比值比1.27,95%CI 1.11-1.46;I2=5.9%)。
- 在有限研究中,3个月MMP-7变化与结局无关。
临床怎么用
- 基线MMP-7可作为未治疗IPF患者预后评估的潜在生物标志物。
- 短期MMP-7变化不宜用于监测疾病进展。
局限性
- 3个月MMP-7变化分析基于有限研究。
- 基线MMP-7与死亡风险的合并分析存在中度异质性(I2=64.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blood-derived biomarkers have been described extensively as potential prognostic markers in idiopathic pulmonary fibrosis (IPF), but studies have been limited by analyses using data-dependent thresholds, inconsistent adjustment for confounders and an array of end-points, thus often yielding ungeneralisable results. Meta-analysis of individual participant data (IPD) is a powerful tool to overcome these limitations. Through systematic review of blood-derived biomarkers, sufficient studies with measurements of matrix metalloproteinase (MMP)-7 were identified to facilitate standardised analyses of the prognostic potential of this biomarker in IPF. METHODS: Electronic databases were searched on 12 November 2020 to identify prospective studies reporting outcomes in patients with untreated IPF, stratified according to at least one pre-specified biomarker, measured at either baseline, or change over 3 months. IPD were sought for studies investigating MMP-7 as a prognostic factor. The primary outcome was overall mortality according to standardised MMP-7 z-scores, with a secondary outcome of disease progression in 12 months, all adjusted for age, gender, smoking and baseline forced vital capacity. RESULTS: IPD was available for nine studies out of 12 identified, reporting outcomes from 1664 participants. Baseline MMP-7 levels were associated with increased mortality risk (adjusted hazard ratio 1.23, 95% CI 1.03-1.48; I2=64.3%) and disease progression (adjusted OR 1.27, 95% CI 1.11-1.46; I2=5.9%). In limited studies, 3-month change in MMP-7 was not associated with outcomes. CONCLUSION: IPD meta-analysis demonstrated that greater baseline MMP-7 levels were independently associated with an increased risk of poor outcomes in patients with untreated IPF, while short-term changes did not reflect disease progression.
引用
- Khan FA, Stewart I, Saini G, et al. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. 2021. PMID: 34588192. doi:10.1183/13993003.01612-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。